A new study exploring the investigational therapy, Zorpo-cel, met its primary safety and secondary efficacy endpoints in ...
H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved ...
Climb Bio (NASDAQ:CLYM) outlined a slate of near-term clinical milestones and its broader autoimmune disease strategy during a fireside chat at the Guggenheim Emerging Outlook Biotech Summit 2026, wit ...
Please provide your email address to receive an email when new articles are posted on . WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over ...
Please provide your email address to receive an email when new articles are posted on . A novel bispecific chimeric antigen receptor T-cell therapy appeared safe and effective for younger patients ...
Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC. Safety and efficacy results of ...
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report The ...
Optimally positioning CD19-directed therapies in the follicular lymphoma treatment sequence requires consideration of both efficacy and the risk of sacrificing future options. The introduction of CD19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results